Stay updated on SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial
Sign up to get notified when there's something new on the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page.

Latest updates to the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedPublications are now described as auto-filled from PubMed and possibly not about the study. The page revision has been updated to v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the operating status notice about government funding and NIH Clinical Center operations. The notice previously warned about potential delays and status updates unrelated to the study details.SummaryDifference0.4%

- Check42 days agoChange DetectedResults data for the SWIPE trial (NCT02705820) have been added, including primary and secondary outcomes and adverse events, with updated study record dates reflecting posted results.SummaryDifference0.5%

- Check71 days agoChange DetectedCore content updated to v3.2.0 with a government-operating-status notice and a removal of the previous v3.1.0 marker.SummaryDifference3%

- Check78 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check92 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2; Back to Top removed.SummaryDifference0.2%

Stay in the know with updates to SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page.